Table 2.
Patient characteristics
| Men | Women | All | |
|---|---|---|---|
| % | 75.6 | 24.4 | 100.0 |
| Age [25–75 % percentile] | 72 [64–79] | 73 [65–81] | 72 [64–79] |
| Morphology | |||
| Non-inv pap trans carcinoma low-grade | 43.4 | 43.0 | 43.4 |
| Non-inv pap trans carcinoma high-grade | 7.6 | 5.6 | 7.1 |
| Displasia | 3.9 | 4.1 | 3.9 |
| Carcinoma in situ | 3.7 | 3.1 | 3.6 |
| Inv trans carcinoma | 41.3 | 44.3 | 42.0 |
| Stage | |||
| Localised | 91.5 | 89.9 | 91.1 |
| Regional advanced | 5.6 | 5.9 | 5.7 |
| Distant advanced | 2.9 | 4.1 | 3.2 |
| Death | |||
| Bladder cancer | 15.0 | 17.2 | 15.5 |
| Other cancer | 22.1 | 21.4 | 22.0 |
| Other than cancer | 30.2 | 26.2 | 29.1 |
| Unknown | 2.7 | 2.6 | 2.8 |
| Alive | 30.0 | 32.6 | 30.6 |
Distribution of age, morphology group, stage and cause of death by sex and in total in the study population of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway from 1981 to 2014